

Turner Syndrome Market Forecasts to 2034 – Global Analysis By Type (Mosaic Turner Syndrome and Classical Turner Syndrome), Drug Type (Oxandrolone, Oxandrin, Norditropin, Somatropin, Genotropin, Humatrope, Zomacton and Nutropin), Therapy Type, Diagnosis, Route Of Administration, End User and By Geography

<https://marketpublishers.com/r/TA7CA0ACEE76EN.html>

Date: April 2026

Pages: 200

Price: US\$ 4,150.00 (Single User License)

ID: TA7CA0ACEE76EN

Abstracts

According to Statistics MRC, the Global Turner Syndrome Market is accounted for \$5.3 billion in 2026 and is expected to reach \$9.8 billion by 2034 growing at a CAGR of 8.1% during the forecast period. Turner syndrome is a chromosomal condition that affects females and results from a missing or incomplete X chromosome. Typically, females have two X chromosomes (XX), but individuals with Turner syndrome have either a missing X chromosome (X0) or abnormalities in one of the X chromosomes. Girls with turner syndrome often have specific physical characteristics including short stature, a webbed neck (extra folds of skin), a broad chest, low-set ears, and a high-arched palate.

According to the National Library of Medicine in 2017, about 1 in 2,500 new-born girls, worldwide, were affected with the Turner Syndrome.

Market Dynamics:

Driver:

Rising patient advocacy and awareness

Patient advocacy plays a crucial role in advocating for improved access to healthcare services and treatments. It often extends to policy initiatives aimed at improving the overall landscape for individuals with rare diseases like Turner syndrome. Increased awareness often leads to early detection of Turner syndrome. It plays a crucial role in raising awareness, supporting research, and advocating for better treatment options. These groups facilitate collaboration between researchers, clinicians, and pharmaceutical companies.

Restraint:

Limited patient population

Turner Syndrome is a rare disorder which occurs in mostly one out of 2000 girls. So, there is less availability of natural history data, which is crucial for understanding the progression of the disease. Limited patient numbers makes it challenging to gather sufficient real-world evidence, potentially hindering the understanding of the long-term impact of therapies. Also, establishing the value of a therapy and securing reimbursement can be more complex. This aspect raises the complexities and hampers the market growth.

Opportunity:

Unmet medical needs

Turner Syndrome is a rare disorder and it presents several unmet medical needs that need effective and targeted therapies. Addressing these unmet medical needs requires collaboration between healthcare professionals, researchers, and pharmaceutical companies. The development of targeted therapies could significantly improve the management of Turner Syndrome, potentially leading to more effective and personalized treatment options. Pharmaceutical companies may see this as an opportunity to develop innovative treatments which in turn accelerates the market expansion.

Threat:

High development costs

The development of therapies for rare conditions such as Turner syndrome often faces unique challenges, leading to high development costs. The limited number of potential

patients makes it economically challenging for pharmaceutical companies to invest in the development of drugs or therapies for Turner syndrome. Also, understanding the underlying genetic mechanisms, conducting preclinical studies, and navigating the regulatory processes for rare diseases require specialized expertise and resources. The combination of these factors can hamper the growth of the market.

Covid-19 Impact

Global healthcare services have been severely impacted by the COVID-19 epidemic. Due to the pandemic, resources were redirected, which caused delays in the treatment of non-urgent medical disorders, such as Turner syndrome. Patients have faced challenges in accessing regular check-ups, treatments, and support services. Additionally, the supply chain for the pharmaceutical sector experienced interruptions that impacted the availability of drugs and other healthcare supplies related to Turner syndrome. The market has further recovered to its pre-pandemic level.

The genotropin segment is expected to be the largest during the forecast period

The genotropin segment is estimated to have a lucrative growth. Genotropin is often used as part of a comprehensive treatment approach that includes hormone replacement therapy and other interventions to address various aspects of Turner syndrome. It contributes to an improved quality of life for individuals with Turner syndrome. It exhibits numerous benefits such as improved body composition, bone health, cardiovascular health, improvement of short stature and overall body growth.

The prenatal testing segment is expected to have the highest CAGR during the forecast period

The prenatal testing segment is anticipated to witness the highest CAGR growth during the forecast period. Prenatal testing plays a crucial role in the early diagnosis of Turner syndrome. This early diagnosis can lead to timely interventions and appropriate management strategies, potentially improving outcomes for the affected individual. Knowing about the disorder during pregnancy allows parents to emotionally prepare for the challenges associated with the condition. As technology and genetic testing methods continue to advance, the accuracy and accessibility of prenatal testing for Turner syndrome are likely to improve, further enhancing its role in patient care and family planning.

Region with largest share:

Asia Pacific is projected to hold the largest market share during the forecast period owing to the increasing awareness for women health, rising healthcare expenditures and growing healthcare sector. The Indian healthcare sector was one of the fastest growing industries. The developing countries like the India and China are investing heavily on healthcare infrastructure, professional doctors and R&D activities. Therefore, the increasing expenditure coupled with rising regularity of genetic disorders in females leads to the growth of the turner syndrome market in this region.

Region with highest CAGR:

Europe is projected to have the highest CAGR over the forecast period. Europe is home to several key players such as Novartis, Ipsen and Sanofi Genzym. These companies invest hugely on research activities related to rare genetic diseases. They often bring out latest innovations and solutions. Further, rise in technological innovations for rare disorders, huge patient population, increasing awareness regarding down syndromes and growing biotechnology sector are boosting the region's market growth.

Key players in the market

Some of the key players profiled in the Turner Syndrome Market include Smiths Group, Pfizer Inc., Rocket Medical PLC, Medtronic, Novo Nordisk, Sanofi, Cooper Pharma, Eli Lilly and Company, Genentech, Lupin Pharmaceuticals Inc, Sandoz International GmbH, AbbVie Inc., Codexis, Merck & Co., American Gene Technologies, Johnson & Johnson Services Inc, F. Hoffmann-La Roche Limited, Ultragenyx Pharmaceutical, Abbott Laboratories and BioMarin.

Key Developments:

In October 2023, Novo Nordisk, a subsidiary of Novo Holdings AS, unveils Somapacitan (Sogroya) is a human growth hormone analog. It is formulated as solution for subcutaneous route of administration. Sogroya is indicated for the replacement of endogenous growth hormone (GH) in adults with growth hormone deficiency (GHD).

In March 2023, Sanofi and Provention Bio Inc, have entered into an agreement under which Sanofi has agreed to acquire Provention Bio, Inc. The acquisition is a strategic fit for Sanofi at the intersection of the company's growth in immune-mediated diseases and disease-modifying therapies in areas of high unmet need, and its expertise in diabetes.

Types Covered:

Mosaic Turner Syndrome

Classical Turner Syndrome

Drug Types Covered:

Oxandrolone

Oxandrin

Norditropin

Somatropin

Genotropin

Humatrope

Zomacton

Nutropin

Therapy Types Covered:

Progesterone Replacement Therapy

Oestrogen Replacement Therapy

Growth Hormone Therapy

Psychological Therapy

Other Therapy Types

Diagnosis Covered:

Physical Examination

Karyotyping

Prenatal Testing

Other Diagnosis

Route Of Administrations Covered:

Oral

Sub-cutaneous

Intravenous

Intramuscular

Other Route Of Administrations

End Users Covered:

Research Organizations

Hospitals & Clinics

Academic Institutes

Other End Users

Regions Covered:

North America

US

Canada

Mexico

Europe

Germany

UK

Italy

France

Spain

Rest of Europe

Asia Pacific

Japan

China

India

Australia

New Zealand

South Korea

Rest of Asia Pacific

South America

Argentina

Brazil

Chile

Rest of South America

Middle East & Africa

Saudi Arabia

UAE

Qatar

South Africa

Rest of Middle East & Africa

What our report offers:

Market share assessments for the regional and country-level segments

Strategic recommendations for the new entrants

Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034

Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)

Strategic recommendations in key business segments based on the market estimations

Competitive landscaping mapping the key common trends

Company profiling with detailed strategies, financials, and recent developments

Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

Company Profiling

Comprehensive profiling of additional market players (up to 3)

SWOT Analysis of key players (up to 3)

Regional Segmentation

Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)

Competitive Benchmarking

Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Contents

1 EXECUTIVE SUMMARY

2 PREFACE

- 2.1 Abstract
- 2.2 Stake Holders
- 2.3 Research Scope
- 2.4 Research Methodology
 - 2.4.1 Data Mining
 - 2.4.2 Data Analysis
 - 2.4.3 Data Validation
 - 2.4.4 Research Approach
- 2.5 Research Sources
 - 2.5.1 Primary Research Sources
 - 2.5.2 Secondary Research Sources
 - 2.5.3 Assumptions

3 MARKET TREND ANALYSIS

- 3.1 Introduction
- 3.2 Drivers
- 3.3 Restraints
- 3.4 Opportunities
- 3.5 Threats
- 3.6 End User Analysis
- 3.7 Emerging Markets
- 3.8 Impact of Covid-19

4 PORTERS FIVE FORCE ANALYSIS

- 4.1 Bargaining power of suppliers
- 4.2 Bargaining power of buyers
- 4.3 Threat of substitutes
- 4.4 Threat of new entrants
- 4.5 Competitive rivalry

5 GLOBAL TURNER SYNDROME MARKET, BY TYPE

- 5.1 Introduction
- 5.2 Mosaic Turner Syndrome
- 5.3 Classical Turner Syndrome

6 GLOBAL TURNER SYNDROME MARKET, BY DRUG TYPE

- 6.1 Introduction
- 6.2 Oxandrolone
- 6.3 Oxandrin
- 6.4 Norditropin
- 6.5 Somatropin
- 6.6 Genotropin
- 6.7 Humatrope
- 6.8 Zomacton
- 6.9 Nutropin

7 GLOBAL TURNER SYNDROME MARKET, BY THERAPY TYPE

- 7.1 Introduction
- 7.2 Progesterone Replacement Therapy
- 7.3 Oestrogen Replacement Therapy
- 7.4 Growth Hormone Therapy
- 7.5 Psychological Therapy
- 7.6 Other Therapy Types

8 GLOBAL TURNER SYNDROME MARKET, BY DIAGNOSIS

- 8.1 Introduction
- 8.2 Physical Examination
- 8.3 Karyotyping
- 8.4 Prenatal Testing
 - 8.4.1 Amniocentesis
 - 8.4.2 Ultrasound Test
 - 8.4.3 Chorionic Villus Sampling
- 8.5 Other Diagnosis

9 GLOBAL TURNER SYNDROME MARKET, BY ROUTE OF ADMINISTRATION

- 9.1 Introduction
- 9.2 Oral
- 9.3 Sub-cutaneous
- 9.4 Intravenous
- 9.5 Intramuscular
- 9.6 Other Route Of Administrations

10 GLOBAL TURNER SYNDROME MARKET, BY END USER

- 10.1 Introduction
- 10.2 Research Organizations
- 10.3 Hospitals & Clinics
- 10.4 Academic Institutes
- 10.5 Other End Users

11 GLOBAL TURNER SYNDROME MARKET, BY GEOGRAPHY

- 11.1 Introduction
- 11.2 North America
 - 11.2.1 US
 - 11.2.2 Canada
 - 11.2.3 Mexico
- 11.3 Europe
 - 11.3.1 Germany
 - 11.3.2 UK
 - 11.3.3 Italy
 - 11.3.4 France
 - 11.3.5 Spain
 - 11.3.6 Rest of Europe
- 11.4 Asia Pacific
 - 11.4.1 Japan
 - 11.4.2 China
 - 11.4.3 India
 - 11.4.4 Australia
 - 11.4.5 New Zealand
 - 11.4.6 South Korea
 - 11.4.7 Rest of Asia Pacific
- 11.5 South America
 - 11.5.1 Argentina

- 11.5.2 Brazil
- 11.5.3 Chile
- 11.5.4 Rest of South America
- 11.6 Middle East & Africa
 - 11.6.1 Saudi Arabia
 - 11.6.2 UAE
 - 11.6.3 Qatar
 - 11.6.4 South Africa
 - 11.6.5 Rest of Middle East & Africa

12 KEY DEVELOPMENTS

- 12.1 Agreements, Partnerships, Collaborations and Joint Ventures
- 12.2 Acquisitions & Mergers
- 12.3 New Product Launch
- 12.4 Expansions
- 12.5 Other Key Strategies

13 COMPANY PROFILING

- 13.1 Smiths Group
- 13.2 Pfizer Inc.
- 13.3 Rocket Medical PLC
- 13.4 Medtronic
- 13.5 Novo Nordisk
- 13.6 Sanofi
- 13.7 Cooper Pharma
- 13.8 Eli Lilly and Company
- 13.9 Genentech
- 13.10 Lupin Pharmaceuticals Inc
- 13.11 Sandoz International GmbH
- 13.12 AbbVie Inc.
- 13.13 Codexis
- 13.14 Merck & Co.
- 13.15 American Gene Technologies
- 13.16 Johnson & Johnson Services Inc
- 13.17 F. Hoffmann-La Roche Limited
- 13.18 Ultragenyx Pharmaceutical
- 13.19 Abbott Laboratories

13.20 BioMarin

List Of Tables

LIST OF TABLES

Table 1 Global Turner Syndrome Market Outlook, By Region (2023–2034) (\$MN)

Table 2 Global Turner Syndrome Market Outlook, By Type (2023–2034) (\$MN)

Table 3 Global Turner Syndrome Market Outlook, By Mosaic Turner Syndrome (2023–2034) (\$MN)

Table 4 Global Turner Syndrome Market Outlook, By Classical Turner Syndrome (2023–2034) (\$MN)

Table 5 Global Turner Syndrome Market Outlook, By Drug Type (2023–2034) (\$MN)

Table 6 Global Turner Syndrome Market Outlook, By Oxandrolone (2023–2034) (\$MN)

Table 7 Global Turner Syndrome Market Outlook, By Oxandrin (2023–2034) (\$MN)

Table 8 Global Turner Syndrome Market Outlook, By Norditropin (2023–2034) (\$MN)

Table 9 Global Turner Syndrome Market Outlook, By Somatropin (2023–2034) (\$MN)

Table 10 Global Turner Syndrome Market Outlook, By Genotropin (2023–2034) (\$MN)

Table 11 Global Turner Syndrome Market Outlook, By Humatrope (2023–2034) (\$MN)

Table 12 Global Turner Syndrome Market Outlook, By Zomacton (2023–2034) (\$MN)

Table 13 Global Turner Syndrome Market Outlook, By Nutropin (2023–2034) (\$MN)

Table 14 Global Turner Syndrome Market Outlook, By Therapy Type (2023–2034) (\$MN)

Table 15 Global Turner Syndrome Market Outlook, By Progesterone Replacement Therapy (2023–2034) (\$MN)

Table 16 Global Turner Syndrome Market Outlook, By Oestrogen Replacement Therapy (2023–2034) (\$MN)

Table 17 Global Turner Syndrome Market Outlook, By Growth Hormone Therapy (2023–2034) (\$MN)

Table 18 Global Turner Syndrome Market Outlook, By Psychological Therapy (2023–2034) (\$MN)

Table 19 Global Turner Syndrome Market Outlook, By Other Therapy Types (2023–2034) (\$MN)

Table 20 Global Turner Syndrome Market Outlook, By Diagnosis (2023–2034) (\$MN)

Table 21 Global Turner Syndrome Market Outlook, By Physical Examination (2023–2034) (\$MN)

Table 22 Global Turner Syndrome Market Outlook, By Karyotyping (2023–2034) (\$MN)

Table 23 Global Turner Syndrome Market Outlook, By Prenatal Testing (2023–2034) (\$MN)

Table 24 Global Turner Syndrome Market Outlook, By Amniocentesis (2023–2034) (\$MN)

Table 25 Global Turner Syndrome Market Outlook, By Ultrasound Test (2023–2034) (\$MN)

Table 26 Global Turner Syndrome Market Outlook, By Chorionic Villus Sampling (2023–2034) (\$MN)

Table 27 Global Turner Syndrome Market Outlook, By Other Diagnosis (2023–2034) (\$MN)

Table 28 Global Turner Syndrome Market Outlook, By Route Of Administration (2023–2034) (\$MN)

Table 29 Global Turner Syndrome Market Outlook, By Oral (2023–2034) (\$MN)

Table 30 Global Turner Syndrome Market Outlook, By Sub-cutaneous (2023–2034) (\$MN)

Table 31 Global Turner Syndrome Market Outlook, By Intravenous (2023–2034) (\$MN)

Table 32 Global Turner Syndrome Market Outlook, By Intramuscular (2023–2034) (\$MN)

Table 33 Global Turner Syndrome Market Outlook, By Other Route Of Administrations (2023–2034) (\$MN)

Table 34 Global Turner Syndrome Market Outlook, By End User (2023–2034) (\$MN)

Table 35 Global Turner Syndrome Market Outlook, By Research Organizations (2023–2034) (\$MN)

Table 36 Global Turner Syndrome Market Outlook, By Hospitals & Clinics (2023–2034) (\$MN)

Table 37 Global Turner Syndrome Market Outlook, By Academic Institutes (2023–2034) (\$MN)

Table 38 Global Turner Syndrome Market Outlook, By Other End Users (2023–2034) (\$MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.

I would like to order

Product name: Turner Syndrome Market Forecasts to 2034 – Global Analysis By Type (Mosaic Turner Syndrome and Classical Turner Syndrome), Drug Type (Oxandrolone, Oxandrin, Norditropin, Somatropin, Genotropin, Humatrope, Zomacton and Nutropin), Therapy Type, Diagnosis, Route Of Administration, End User and By Geography

Product link: <https://marketpublishers.com/r/TA7CA0ACEE76EN.html>

Price: US\$ 4,150.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/TA7CA0ACEE76EN.html>